Potassium-Increasing Regimens in Patients at High Risk of Ventricular Arrhythmias: A Prespecified Observational Analysis of the Randomized POTCAST Trial

Clicks: 70
ID: 331466
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #5 of 137 articles by views in EP Europace

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 137 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND AND AIMS: The POTCAST trial (n=1,200) showed that targeting high-normal plasma potassium levels reduced ventricular arrhythmias in patients with Implantable Cardioverter-Defibrillators (ICDs). We compared changes in plasma potassium and described outcomes across the three regimens used to increase plasma potassium. METHODS: We studied 600 control participants and 572 intervention participants who completed potassium up-titration in POTCAST. Participants in the intervention arm were categorized according to treatment after plasma-potassium up-titration into: a) mineralocorticoid-receptor antagonists (MRAs) monotherapy, b) potassium-supplement monotherapy, or c) combination-therapy with both. The primary endpoint was a composite of sustained ventricular arrhythmia, appropriate ICD-therapy, hospitalization for arrhythmia or heart-failure or all-cause mortality. Safety outcomes included death and electrolyte/renal disturbances. RESULTS: After six months, plasma potassium increased from 4.12 to 4.27 mmol/L (p=0.004) with MRA, from 3.99 to 4.24 mmol/L (p<0.001) with potassium-supplements, and from 3.98 to 4.34 mmol/L (p<0.001) with combination-therapy. The primary endpoint occurred in 29% (n=175) of controls, 22% (n=16) in the MRA group, 21% (n=31) in the potassium-supplements group and in 22% (n=72) in the combination-therapy group (p=0.8 between regimens). Hypokalemia occurred in 13% of controls and in 3%, 9%, and 5% of participants receiving MRA, potassium-supplements and combination-therapy, respectively. Hyperkalemia occurred in 0.2% of controls and in 0%, 3%, and 4% of participants receiving MRA, potassium-supplements, and combination-therapy (p>0.1 between regimens). CONCLUSIONS: Treatment with MRA, potassium-supplements or both increased potassium levels. All regimens were associated with numerically lower endpoint rates than controls. We detected no statistically significant differences in endpoints or safety between regimens.
Reference Key
openalex_W7220648001 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Elisabeth Margrethe Danielsen, Emil Anton Frandsen, Ulrik Winsløw, Chaoqun Zheng, Tharsika Sakthivel, Kasper Karmark Iversen, Helle Skovmand Bosselmann, Niels Risum, Henning Bundgaard, Christian Jøns
Are you one of these authors? Claim your profile
Journal EP Europace
Year 2026
DOI
10.1093/europace/euag272
URL
https://doi.org/10.1093/europace/euag272
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.